Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.

@article{Singer2015LimitedHB,
  title={Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.},
  author={Gamal A. M. Singer and Shannon M Zielsdorf and V A Fleetwood and N. D. S. Alvey and Elaine R. Cohen and Sheila L Eswaran and Nikunj N. Shah and Edie Yee Chan and M. Catherine Hertl and Sameh Adel Fayek},
  journal={Transplantation proceedings},
  year={2015},
  volume={47 2},
  pages={478-84}
}
BACKGROUND Prophylaxis against hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) includes lifelong hepatitis B immunoglobulin (HBIG) and oral antiviral agent(s). In the presence of high-genetic-barrier nucleos(t)ide analogues, the need for lifelong HBIG is questioned. We evaluated the safety and cost-effectiveness of a limited… CONTINUE READING